Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients who underwent antiestrogenic therapy
| Errataetall: |
CommentIn: Ann Oncol. 2021 Jul;32(7):933-934. - PMID 33794291 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Annals of oncology : official journal of the European Society for Medical Oncology - 32(2021), 5 vom: 12. Mai, Seite 676-677 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Montopoli, M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 21.04.2021 Date Revised 30.03.2024 published: Print-Electronic CommentIn: Ann Oncol. 2021 Jul;32(7):933-934. - PMID 33794291 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.annonc.2021.01.069 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320855856 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320855856 | ||
| 003 | DE-627 | ||
| 005 | 20240330235908.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2021.01.069 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1357.xml |
| 035 | |a (DE-627)NLM320855856 | ||
| 035 | |a (NLM)33524477 | ||
| 035 | |a (PII)S0923-7534(21)00097-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Montopoli, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients who underwent antiestrogenic therapy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.04.2021 | ||
| 500 | |a Date Revised 30.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Ann Oncol. 2021 Jul;32(7):933-934. - PMID 33794291 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Zorzi, M |e verfasserin |4 aut | |
| 700 | 1 | |a Cocetta, V |e verfasserin |4 aut | |
| 700 | 1 | |a Prayer-Galetti, T |e verfasserin |4 aut | |
| 700 | 1 | |a Guzzinati, S |e verfasserin |4 aut | |
| 700 | 1 | |a Bovo, E |e verfasserin |4 aut | |
| 700 | 1 | |a Rugge, M |e verfasserin |4 aut | |
| 700 | 1 | |a Calcinotto, A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology : official journal of the European Society for Medical Oncology |d 1990 |g 32(2021), 5 vom: 12. Mai, Seite 676-677 |w (DE-627)NLM012606308 |x 1569-8041 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2021 |g number:5 |g day:12 |g month:05 |g pages:676-677 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.annonc.2021.01.069 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2021 |e 5 |b 12 |c 05 |h 676-677 | ||